• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Cree, I
    Booton, R
    Cane, P
    Gosney, J
    Ibrahim, M
    Kerr, K
    Lal, R
    Lewanski, C
    Navani, N
    Nicholson, A
    Nicolson, M
    Summers, Yvonne J
    Show allShow less
    Affiliation
    Department of Pathology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry
    Issue Date
    2016-05-19
    
    Metadata
    Show full item record
    Abstract
    A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1). Several drugs have been approved or are in the late stages of development targeting PD-1 (pembrolizumab and nivolumab) or PD-L1 (atezolizumab, durvalumab and avelumab). Inevitably, the introduction of these drugs will place pressure on healthcare systems and there is a need to stratify patients to identify those who are most likely to benefit from such treatment. There is evidence that responsiveness to PD-1 inhibitors may be predicted by expression of PD-L1 on neoplastic cells. Hence, there is considerable interest in using PD-L1 immunohistochemical staining to guide the use of PD-1-targeted treatments in patients with NSCLC. This paper reviews the current knowledge about PD-L1 testing and identifies current research requirements. Key factors to consider include the source and timing of sample collection, pre-analytical steps (sample tracking, fixation, tissue processing, sectioning and tissue prioritization), analytical decisions (choice of biomarker assay/kit and automated staining platform, with verification of standardized assays or validation of laboratory-devised techniques, internal and external quality assurance and audit), and reporting and interpretation of the results. This review addresses the need for integration of PD-L1 immunohistochemistry with other tests as part of locally agreed pathways and protocols. There remain areas of uncertainty and guidance should be updated regularly as new information becomes available. This article is protected by copyright. All rights reserved.
    Citation
    PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. 2016: Histopathology
    Journal
    Histopathology
    URI
    http://hdl.handle.net/10541/613327
    DOI
    10.1111/his.12996
    PubMed ID
    27196116
    Type
    Article
    Language
    en
    ISSN
    1365-2559
    ae974a485f413a2113503eed53cd6c53
    10.1111/his.12996
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    • Authors: Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y
    • Issue date: 2018 Mar
    • Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    • Authors: Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J
    • Issue date: 2016 Oct 8
    • Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    • Authors: Villaruz LC, Ancevski Hunter K, Kurland BF, Abberbock S, Herbst C, Dacic S
    • Issue date: 2019 Jan
    • Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    • Authors: Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P
    • Issue date: 2018 Apr
    • The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    • Authors: Villaruz LC, Socinski MA
    • Issue date: 2016 Sep
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.